RR

Reshma Rangwala

Chief Medical Officer & Head of Research

Karyopharm Therapeutics

Karyopharm Therapeutics Pipeline

DrugIndicationPhase
Selinexor (XPOVIO®)Multiple MyelomaApproved/Commercial
SelinexorAcute Myeloid Leukemia (AML)Clinical Trials
Next-Generation SINE CompoundsVarious CancersPre-clinical / Early Clinical